Published in Biochem Pharmacol on December 07, 2012
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38
Crystal structures of the novel cytosolic 5'-nucleotidase IIIB explain its preference for m7GMP. PLoS One (2014) 0.84
Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia? Expert Rev Hematol (2013) 0.75
Beta-hydroxyphosphonate ribonucleoside analogues derived from 4-substituted-1,2,3-triazoles as IMP/GMP mimics: synthesis and biological evaluation. Beilstein J Org Chem (2016) 0.75
The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. Oncotarget (2017) 0.75
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol (2008) 2.31
Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol (2002) 2.23
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
The structure of barley alpha-amylase isozyme 1 reveals a novel role of domain C in substrate recognition and binding: a pair of sugar tongs. Structure (2003) 1.84
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J Med Chem (2008) 1.69
A revised nomenclature for the human and rodent alpha-tubulin gene family. Genomics (2007) 1.68
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer (2007) 1.63
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma (2002) 1.61
Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS One (2009) 1.60
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther (2013) 1.60
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 1.58
Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res (2005) 1.51
Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther (2005) 1.50
A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer (2006) 1.44
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma (2013) 1.43
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol (2010) 1.43
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol (2002) 1.37
Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents (2005) 1.35
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther (2011) 1.33
Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther (2009) 1.32
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer (2010) 1.31
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res (2007) 1.26
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol (2010) 1.25
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res (2002) 1.20
Structure of a full length psychrophilic cellulase from Pseudoalteromonas haloplanktis revealed by X-ray diffraction and small angle X-ray scattering. J Mol Biol (2005) 1.17
Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells (2002) 1.16
Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta (2007) 1.16
Biochemical and molecular characterization of a detergent-stable serine alkaline protease from Bacillus pumilus CBS with high catalytic efficiency. Biochimie (2008) 1.14
Insights into early extracellular matrix evolution: spongin short chain collagen-related proteins are homologous to basement membrane type IV collagens and form a novel family widely distributed in invertebrates. Mol Biol Evol (2006) 1.13
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res (2004) 1.12
Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res (2012) 1.12
mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci (2008) 1.11
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer (2002) 1.11
BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood (2008) 1.10
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer (2005) 1.09
Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol (2006) 1.09
Structural basis of fibrillar collagen trimerization and related genetic disorders. Nat Struct Mol Biol (2012) 1.08
Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma (2004) 1.07
The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer (2009) 1.06
VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability. Retrovirology (2008) 1.03
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res (2008) 1.02
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol (2008) 1.00
Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol (2003) 1.00
Trehalulose synthase native and carbohydrate complexed structures provide insights into sucrose isomerization. J Biol Chem (2007) 1.00
F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells. J Immunol (2010) 1.00
ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. Exp Cell Res (2006) 1.00
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs (2011) 0.99
X-Ray crystal structure of the multidomain endoglucanase Cel9G from Clostridium cellulolyticum complexed with natural and synthetic cello-oligosaccharides. J Bacteriol (2003) 0.99
In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res (2009) 0.99
Oligosaccharide binding to barley alpha-amylase 1. J Biol Chem (2005) 0.98
Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.98
Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol (2009) 0.98
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther (2005) 0.97
Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev (2002) 0.97
Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer (2008) 0.97
The 'pair of sugar tongs' site on the non-catalytic domain C of barley alpha-amylase participates in substrate binding and activity. FEBS J (2007) 0.96
Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol (2009) 0.95
Engineering of the alpha-amylase from Geobacillus stearothermophilus US100 for detergent incorporation. Biotechnol Bioeng (2009) 0.94
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemother Pharmacol (2006) 0.94
ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer (2008) 0.92
Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS One (2012) 0.92
In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. Biochem Pharmacol (2003) 0.92
Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem Biophys Res Commun (2008) 0.92
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. Cell Cycle (2008) 0.92
Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies. Leuk Lymphoma (2003) 0.91
The ABC transporter BmrA from Bacillus subtilis is a functional dimer when in a detergent-solubilized state. Biochem J (2006) 0.91
Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a new, powerful lead. J Med Chem (2003) 0.90
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). Hematol J (2002) 0.90
The linker region plays a key role in the adaptation to cold of the cellulase from an Antarctic bacterium. Biochem J (2007) 0.90
Targeted therapies in metastatic melanoma: toward a clinical breakthrough? Anticancer Agents Med Chem (2010) 0.90
Drug effect unveils inter-head cooperativity and strain-dependent ADP release in fast skeletal actomyosin. J Biol Chem (2009) 0.90
The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica (2005) 0.89
In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood (2003) 0.89
Lipase-catalyzed regioselective monoacetylation of unsymmetrical 1,5-primary diols. J Org Chem (2010) 0.89
Selectivity of kinases on the activation of tenofovir, an anti-HIV agent. Eur J Pharm Sci (2012) 0.89
Probing the role of divalent metal ions in a bacterial psychrophilic metalloprotease: binding studies of an enzyme in the crystalline state by x-ray crystallography. J Bacteriol (2003) 0.89
Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leuk Lymphoma (2005) 0.88
Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood (2010) 0.87
Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Oncogene (2004) 0.87
Enhancement of the thermostability and the catalytic efficiency of Bacillus pumilus CBS protease by site-directed mutagenesis. Biochimie (2010) 0.87
Characterization of an l-arabinose isomerase from the Lactobacillus plantarum NC8 strain showing pronounced stability at acidic pH. FEMS Microbiol Lett (2007) 0.87
Structural insights into the inhibition of cytosolic 5'-nucleotidase II (cN-II) by ribonucleoside 5'-monophosphate analogues. PLoS Comput Biol (2011) 0.86
Genome Sequence of "Candidatus Arthromitus" sp. Strain SFB-Mouse-NL, a Commensal Bacterium with a Key Role in Postnatal Maturation of Gut Immune Functions. Genome Announc (2014) 0.86
Interaction of human 3-phosphoglycerate kinase with its two substrates: is substrate antagonism a kinetic advantage? J Mol Biol (2011) 0.86